Extended Data Table 2 Anti-acetylcholine receptor antibody titer for seropositive RCT patients

From: BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

  1. Measurements were taken at SCR (n = 21), placebo at month 3 (n = 11), and Descartes-08 at month 3 (n = 13), and month 12 (n = 9). Table shows median and interquartile range. Anti-AChR antibody titer did not undergo significant change from SCR to month 3 in placebo or Descartes-08 groups or month 12 in the Descartes-08 group.
Back to article page